Strides sells arm’s manufacturing unit to Syngene International for Rs 702 crore, Top Health News | Latest Healthcare Sector & Healthcare Industry news, Information and Updates: ET HealthWorld : ETHealthworld.com

Strides Pharma Science has agreed to sell the biologics Unit-3 manufacturing facility of its associate company Stelis Biopharma to Syngene International for INR702 crore ($94m) in cash. Syngene will also invest up to INR100 crore to repurpose and revalidate the Bommasandra Industrial Area in Bengaluru site, which is being repurposed to produce monoclonal antibodies., Strides Pharma Science has agreed to sell the biologics Unit-3 manufacturing facility of its associate company Stelis Biopharma to Syngene International for INR702 crore ($94m) in cash. Syngene will also invest up to INR100 crore to repurpose and revalidate the Bommasandra Industrial Area in Bengaluru site, which is being repurposed to produce monoclonal antibodies., , Read More